Free-text search
Content Types
-
Potions, Placebos and Perilous Practices – Macabre Mistakes in the History of Medicine
Tobacco for cancer, heroin for coughs, mercury for teething babies. Humanity’s path towards today’s evidence‑based medicine has been lined with strange misjudge...
-
BioArctic chair: “First, you need to know where you’re going”
He has been a researcher, doctor, investor and business leader. But when Eugen Steiner explains BioArctic’s success, he keeps coming back to the same thing: its...
-
Kodiak shares more than double after positive eye drug results
A successful Phase III trial in age-related macular degeneration sent shares in US-based Kodiak Sciences soaring on Monday.
-
BioArctic steps into cancer research with new collaboration
BioArctic has entered a research collaboration with the Swedish‑Japanese company Mesenkia Therapeutics, marking the company’s first step into the oncology field.
-
CTIS updates strengthen compliance and transparency
The Clinical Trials Information System (CTIS) has introduced several updates aimed at improving safety reporting, communication, and regulatory compliance for sponsors.
-
Swedish electrode technology moves from lab to patients
Fractions of a millimetre can determine whether deep brain stimulation relieves symptoms or causes side effects. Now, after 20 years of research, scientists at ...
-
Danish biosolutions company expands U.S. factory
Novonesis has expanded its facility in the U.S. cheese capital.
-
Elypta awarded one million USD from the Star Trek creator’s foundation
Swedish company Elypta, which develops methods for early cancer detection, has been awarded one million USD from an unexpected source: a foundation set up in me...
-
Elfcare to integrate health data with ChatGPT – leaves sharing to users
Healthcare company Elfcare has launched a new connector that allows users to share results from its health assessments with AI assistants. Speaking to Life Scie...
-
Omnio raises €2.9m for chronic wound therapy
Swedish biotech company Omnio has secured €2.9 million from existing investors and shareholders. The funding will be used to advance its plasminogen-based biolo...
-
GLP-1 drugs spark unexpected interest among perfume giants
The appetite-suppressing effects of weight-loss drugs are well known. But could they also change what people want to smell like? That question has now caught th...
-
Marie Gårdmark: Are FDA and EMA drifting apart?
Are FDA and EMA beginning to drift apart on what it takes to approve new medicines? And what could that mean for drug development on both sides of the Atlantic?...
-
Cavidi Secures US Patent Allowance for BOLD Signal-Amplification Technology
The allowance protects Cavidi's Enzyme Enhanced ELISA invention in the US, five years after its first patent filing in Sweden.
-
Björn Arvidsson: “We skip the most important step after research”
In Sweden, we are proud of our research – and rightly so. We invest substantial resources and have internationally recognised strengths in life science. But whe...
-
Swedish Alzheimer’s project wins 19 million dollar US research grant
An Alzheimer’s research project led by associate professor Sebastian Palmqvist at Lund University has been awarded 19.4 million dollars in US research funding. ...
-
Novartis makes a move in red‑hot radiopharma space
Novartis is expanding its radiopharmaceutical pipeline through a licensing agreement with Chinese BoomRay Therapeutics worth up to 900 million dollars.
-
Multicancer blood test moves closer to FDA approval
A blood test designed to detect signals from more than 50 types of cancer before symptoms appear could be on its way to FDA approval, after an advisory panel of...
-
Swedish biotech AnaCardio raises €62.5m to advance heart failure drug
Swedish biotech company AnaCardio has raised €62.5 million, equivalent to more than SEK 700 million, in its largest funding round to date. “It’s a big day for u...
-
Stem cell setback in infant heart condition
U.S.-based Longeveron plans to implement cost‑saving measures and “explore strategic options” after a Phase II trial failed to meet its primary endpoint in a ra...
-
From diagnosis to treatment, ZEISS introduces innovations across ZEISS Retina Workflow
ZEISS Medical Technology advances its ZEISS Retina Workflow with digital and surgical enhancements, and new imaging technologies.
-
Svenskt biotechbolag tar in 153 miljoner till cancerstudie
One-carbon Therapeutics, ett svenskt biotechbolag med inriktning på svårbehandlad cancer, har tagit in 153 miljoner kronor i en övertecknad investeringsrunda.
-
Natural Cycles sharpens Nordic focus with new regional chief
After nearly a decade at Natural Cycles, Sofie Askervall has stepped into the newly created role of Head of Nordics. “Right now, we are looking closely at Norway,” she says.
-
Study: Nearly 90% of biomedical papers show signs of AI assistance
The use of AI in scientific writing may be far more widespread than previous estimates have suggested. In a new study, almost nine out of ten biomedical papers ...
-
On-demand webinar: ZEISS Lightfield 4D for high-content tumor microtissue screening
From reliable and scalable 3D models to quantitative insights.
BREAKING